Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedRecruitment status on the study page now shows 'No longer looking for participants,' indicating enrollment is complete. The page also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and standardizes the Intervention/Treatment label, with the revision tag updated to v3.6.0.SummaryDifference0.2%

- Check8 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing Revision: v3.5.4. This indicates the page's revision was updated to a newer version.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page's revision tag updated from v3.5.3 to v3.5.4, indicating a minor update to the study details page metadata. This reflects an internal revision rather than changes to the study data or content.SummaryDifference0.0%

- Check50 days agoChange DetectedUpdates the Chile location listing to use shorter region labels (e.g., Araucania and Valparaiso) alongside the corresponding city/state entries, and updates the displayed site revision version.SummaryDifference0.4%

- Check57 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded Padova, Italy, 35128 as a study location and removed Padua, Italy, 35128.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.